1-methyl-4-phenylpyridinium has been researched along with neostigmine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
Atadzhanov, MA; Kryzhanovskiĭ, GN; Nerobkova, LN; Voronina, TA | 1 |
2 other study(ies) available for 1-methyl-4-phenylpyridinium and neostigmine
Article | Year |
---|---|
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
[The characteristics of a parkinsonian syndrome induced in an experiment by a deficiency of nigrostriatal dopamine and by stimulation of the cholinergic neurons of the caudate nucleus].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholine; Animals; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Electroencephalography; Male; Neostigmine; Neurons; Oxotremorine; Parkinson Disease, Secondary; Rats; Receptors, Cholinergic; Substantia Nigra | 1993 |